Aarti Mathur1, Whitney Sutton1, JiYoon B Ahn1, Jason D Prescott1, Martha A Zeiger2, Dorry L Segev1,3, Mara McAdams-DeMarco1,3. 1. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. 2. Surgical Oncology Program, National Cancer Institute, National Institute of Health, Bethesda, MD. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Abstract
BACKGROUND: Secondary hyperparathyroidism (SHPT) affects nearly all patients on maintenance dialysis therapy. SHPT treatment options have considerably evolved over the past 2 decades but vary in degree of improvement in SHPT. Therefore, we hypothesize that the risks of adverse outcomes after kidney transplantation (KT) may differ by SHPT treatment. METHODS: Using the Scientific Registry of Transplant Recipients and Medicare claims data, we identified 5094 adults (age ≥18 y) treated with cinacalcet or parathyroidectomy for SHPT before receiving KT between 2007 and 2016. We quantified the association between SHPT treatment and delayed graft function and acute rejection using adjusted logistic models and tertiary hyperparathyroidism (THPT), graft failure, and death using adjusted Cox proportional hazards; we tested whether these associations differed by patient characteristics. RESULTS: Of 5094 KT recipients who were treated for SHPT while on dialysis, 228 (4.5%) underwent parathyroidectomy, and 4866 (95.5%) received cinacalcet. There was no association between treatment of SHPT and posttransplant delayed graft function, graft failure, or death. However, compared with patients treated with cinacalcet, those treated with parathyroidectomy had a lower risk of developing THPT (adjusted hazard ratio, 0.56; 95% confidence interval, 0.35-0.89) post-KT. Furthermore, this risk differed by dialysis vintage (Pinteraction = 0.039). Among patients on maintenance dialysis therapy for ≥3 y before KT (n = 3477, 68.3%), the risk of developing THPT was lower when treated with parathyroidectomy (adjusted hazard ratio, 0.43; 95% confidence interval, 0.24-0.79). CONCLUSIONS: Parathyroidectomy should be considered as treatment for SHPT, especially in KT candidates on maintenance dialysis for ≥3 y. Additionally, patients treated with cinacalcet for SHPT should undergo close surveillance for development of tertiary hyperparathyroidism post-KT.
BACKGROUND: Secondary hyperparathyroidism (SHPT) affects nearly all patients on maintenance dialysis therapy. SHPT treatment options have considerably evolved over the past 2 decades but vary in degree of improvement in SHPT. Therefore, we hypothesize that the risks of adverse outcomes after kidney transplantation (KT) may differ by SHPT treatment. METHODS: Using the Scientific Registry of Transplant Recipients and Medicare claims data, we identified 5094 adults (age ≥18 y) treated with cinacalcet or parathyroidectomy for SHPT before receiving KT between 2007 and 2016. We quantified the association between SHPT treatment and delayed graft function and acute rejection using adjusted logistic models and tertiary hyperparathyroidism (THPT), graft failure, and death using adjusted Cox proportional hazards; we tested whether these associations differed by patient characteristics. RESULTS: Of 5094 KT recipients who were treated for SHPT while on dialysis, 228 (4.5%) underwent parathyroidectomy, and 4866 (95.5%) received cinacalcet. There was no association between treatment of SHPT and posttransplant delayed graft function, graft failure, or death. However, compared with patients treated with cinacalcet, those treated with parathyroidectomy had a lower risk of developing THPT (adjusted hazard ratio, 0.56; 95% confidence interval, 0.35-0.89) post-KT. Furthermore, this risk differed by dialysis vintage (Pinteraction = 0.039). Among patients on maintenance dialysis therapy for ≥3 y before KT (n = 3477, 68.3%), the risk of developing THPT was lower when treated with parathyroidectomy (adjusted hazard ratio, 0.43; 95% confidence interval, 0.24-0.79). CONCLUSIONS: Parathyroidectomy should be considered as treatment for SHPT, especially in KT candidates on maintenance dialysis for ≥3 y. Additionally, patients treated with cinacalcet for SHPT should undergo close surveillance for development of tertiary hyperparathyroidism post-KT.
Authors: Geoffrey A Block; David A Bushinsky; Sunfa Cheng; John Cunningham; Bastian Dehmel; Tilman B Drueke; Markus Ketteler; Reshma Kewalramani; Kevin J Martin; Sharon M Moe; Uptal D Patel; Justin Silver; Yan Sun; Hao Wang; Glenn M Chertow Journal: JAMA Date: 2017-01-10 Impact factor: 56.272
Authors: Rachel L Yang; Kate Freeman; Caroline E Reinke; Douglas L Fraker; Giorgos C Karakousis; Rachel R Kelz; Alden M Doyle Journal: Transplantation Date: 2012-07-15 Impact factor: 4.939
Authors: Simon A Littbarski; Alexander Kaltenborn; Jill Gwiasda; Jan Beneke; Viktor Arelin; Ysabell Schwager; Julia V Stupak; Indra L Marcheel; Nikos Emmanouilidis; Mark D Jäger; Georg Friedrich Wilhelm Scheumann; Jürgen Klempnauer; Harald Schrem Journal: Surgery Date: 2017-12-25 Impact factor: 3.982
Authors: Douglas S Fuller; Shan Xing; Vasily Belozeroff; Alon Yehoshua; Hal Morgenstern; Bruce M Robinson; Robert J Rubin; Nisha Bhatt; Ronald L Pisoni Journal: Clin J Am Soc Nephrol Date: 2019-01-21 Impact factor: 8.237
Authors: Irene Ruderman; Stephen G Holt; Geoffrey S Kirkland; Sophie Maslen; Carmel M Hawley; Veronica Oliver; Rathika Krishnasamy; Nicholas A Gray; Girish S Talaulikar; Craig L Nelson; Yogeshwar Rajaram; Hilton Gock; Eric Au; Grahame J Elder; Rahul Mainra; Nigel D Toussaint Journal: Intern Med J Date: 2019-01 Impact factor: 2.048
Authors: Aarti Mathur; JiYoon B Ahn; Whitney Sutton; Martha A Zeiger; Dorry L Segev; Mara McAdams-DeMarco Journal: Surgery Date: 2022-03-21 Impact factor: 4.348